董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Myers | 男 | Director and Chairperson | 60 | 18.41万美元 | 未持股 | 2026-05-22 |
| Julie Eastland | 女 | Director, President and Chief Executive Officer | 62 | 130.07万美元 | 47.51 | 2026-05-22 |
| Jan Skvarka | 男 | Director | 59 | 15.14万美元 | 13.73 | 2026-05-22 |
| David M. Johnson | 男 | Director | 61 | 13.93万美元 | 24.53 | 2026-05-22 |
| Enoch Kariuki | 男 | Director | 44 | 15.14万美元 | 12.18 | 2026-05-22 |
| Luke Walker | 男 | Director | 54 | 14.53万美元 | 3.84 | 2026-05-22 |
| Shannon Campbell | 女 | Director | -- | 未披露 | 未持股 | 2026-05-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James B. Bucher | 男 | Chief Legal Officer and Corporate Secretary | 60 | 66.00万美元 | 未持股 | 2026-05-22 |
| Julie Eastland | 女 | Director, President and Chief Executive Officer | 62 | 130.07万美元 | 47.51 | 2026-05-22 |
| Ingmar Bruns | -- | Chief Medical Officer | 51 | 86.98万美元 | 未持股 | 2026-05-22 |
董事简历
中英对照 | 中文 | 英文- Scott Myers
-
Scott Myers，他曾担任Zentalis Pharmaceuticals， Inc.的董事会成员和主席。自2024年11月起担任董事会成员。此前，他曾担任Viridian Therapeutics， Inc.（纳斯达克股票代码：VRDN）的总裁、首席执行官和董事会成员（从2023年2月到2023年11月）。在Viridian之前，Myers先生从2020年4月起担任AMAG Pharmaceuticals， Inc.的首席执行官兼董事会成员，直到该公司被Covis Group S。à。r.l收购。2020年11月。Myers先生担任Rainier Therapeutics, Inc.首席执行官和董事会主席、一个私人oncology-focused生物科技公司，从2018年到2020年当它导致资产被融合制药公司，作为总裁，首席执行官和董事会成员Cascadian Therapeutics Inc.（fkaOncothyreon, Inc .），或Cascadian，从2016年直到它被Seagen, Inc.收购 （fka Seattle Genetics, Inc.），或Seagen， 2018年。Myers先生自2024年3月起担任Convergent Therapeutics， Inc.的董事会主席，自2021年10月起担任Dynavax Technologies Corporation或Dynavax（纳斯达克股票代码：DVAX）的董事会主席，并自2024年11月起担任Umoja Biopharma， Inc.的董事会成员。Myers先生自2018年8月起担任Harpoon Therapeutics， Inc.或Harpoon的董事会成员，并自2021年10月起担任Harpoon的董事长，直到Harpoon于2024年3月被Merck & Co., Inc.或Merck（纽约证券交易所代码：MRK）收购。Myers先生此前从2019年6月起担任Selecta Biosciences， Inc.的董事会成员，直到其于2023年11月与Cartesian Therapeutics， Inc.（纳斯达克股票：RNAC）合并；从2021年4月起担任Trillium Therapeutics Inc.或Trillium的董事会成员，直到其于2021年11月被Pfizer Inc.或Pfizer（纽约证券交易所股票：PFE）收购；从2022年4月起担任Ironshore Therapeutics Inc.的董事会主席，直到其被Collegium Pharmaceutical Inc.（纳斯达克股票：PFE）收购。Sensorion S.A. （EPA： ALSEN），期限为2021年12月至2023年3月。他持有Northwestern大学的生物学学士学位和the Graduate School of Business （Booth） at Chicago大学的工商管理硕士学位。
Scott Myers,has served as a member of Board and as the Chairperson of Zentalis Pharmaceuticals, Inc. Board since November 2024. Previously, Mr. Myers served as President, Chief Executive Officer and a member of the Board of Directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) from February 2023 to November 2023. Prior to Viridian, Mr. Myers served as Chief Executive Officer and a member of the Board of Directors of AMAG Pharmaceuticals, Inc. from April 2020 until it was acquired by Covis Group S.à.r.l. in November 2020. Mr. Myers served as Chief Executive Officer and Chairman of the Board of Directors of Rainier Therapeutics, Inc., a private oncology-focused biotechnology company, from 2018 to 2020 when its lead asset was purchased by Fusion Pharmaceuticals Inc., and as President, Chief Executive Officer and a member of the Board of Directors of Cascadian Therapeutics Inc. (fkaOncothyreon, Inc.), or Cascadian, from 2016 until it was acquired by Seagen, Inc. (fka Seattle Genetics, Inc.), or Seagen, in 2018. Mr. Myers has served as Chairperson of the Board of Directors of Convergent Therapeutics, Inc. since March 2024, as Chairperson of the Board of Directors of Dynavax Technologies Corporation, or Dynavax (Nasdaq: DVAX), since October 2021, and as a member of the Board of Directors of Umoja Biopharma, Inc. since November 2024. Mr. Myers also served as a member of the Board of Directors of Harpoon Therapeutics, Inc., or Harpoon, from August 2018, and as Chairman of Harpoon from October 2021, until Harpoon was acquired by Merck & Co., Inc., or Merck (NYSE: MRK), in March 2024. Mr. Myers previously served as a member of the Boards of Directors of Selecta Biosciences, Inc. from June 2019 until its merger with Cartesian Therapeutics, Inc. (Nasdaq: RNAC) in November 2023, and Trillium Therapeutics Inc., or Trillium, from April 2021 until its acquisition by Pfizer Inc., or Pfizer (NYSE: PFE), in November 2021, and as Chairperson of the Board of Directors of Ironshore Therapeutics Inc. from April 2022 until its acquisition by Collegium Pharmaceutical Inc. (Nasdaq: COLL) in September 2024, and Sensorion S.A. (EPA: ALSEN) from December 2021 to March 2023. Mr. Myers received a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago. - Scott Myers，他曾担任Zentalis Pharmaceuticals， Inc.的董事会成员和主席。自2024年11月起担任董事会成员。此前，他曾担任Viridian Therapeutics， Inc.（纳斯达克股票代码：VRDN）的总裁、首席执行官和董事会成员（从2023年2月到2023年11月）。在Viridian之前，Myers先生从2020年4月起担任AMAG Pharmaceuticals， Inc.的首席执行官兼董事会成员，直到该公司被Covis Group S。à。r.l收购。2020年11月。Myers先生担任Rainier Therapeutics, Inc.首席执行官和董事会主席、一个私人oncology-focused生物科技公司，从2018年到2020年当它导致资产被融合制药公司，作为总裁，首席执行官和董事会成员Cascadian Therapeutics Inc.（fkaOncothyreon, Inc .），或Cascadian，从2016年直到它被Seagen, Inc.收购 （fka Seattle Genetics, Inc.），或Seagen， 2018年。Myers先生自2024年3月起担任Convergent Therapeutics， Inc.的董事会主席，自2021年10月起担任Dynavax Technologies Corporation或Dynavax（纳斯达克股票代码：DVAX）的董事会主席，并自2024年11月起担任Umoja Biopharma， Inc.的董事会成员。Myers先生自2018年8月起担任Harpoon Therapeutics， Inc.或Harpoon的董事会成员，并自2021年10月起担任Harpoon的董事长，直到Harpoon于2024年3月被Merck & Co., Inc.或Merck（纽约证券交易所代码：MRK）收购。Myers先生此前从2019年6月起担任Selecta Biosciences， Inc.的董事会成员，直到其于2023年11月与Cartesian Therapeutics， Inc.（纳斯达克股票：RNAC）合并；从2021年4月起担任Trillium Therapeutics Inc.或Trillium的董事会成员，直到其于2021年11月被Pfizer Inc.或Pfizer（纽约证券交易所股票：PFE）收购；从2022年4月起担任Ironshore Therapeutics Inc.的董事会主席，直到其被Collegium Pharmaceutical Inc.（纳斯达克股票：PFE）收购。Sensorion S.A. （EPA： ALSEN），期限为2021年12月至2023年3月。他持有Northwestern大学的生物学学士学位和the Graduate School of Business （Booth） at Chicago大学的工商管理硕士学位。
- Scott Myers,has served as a member of Board and as the Chairperson of Zentalis Pharmaceuticals, Inc. Board since November 2024. Previously, Mr. Myers served as President, Chief Executive Officer and a member of the Board of Directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) from February 2023 to November 2023. Prior to Viridian, Mr. Myers served as Chief Executive Officer and a member of the Board of Directors of AMAG Pharmaceuticals, Inc. from April 2020 until it was acquired by Covis Group S.à.r.l. in November 2020. Mr. Myers served as Chief Executive Officer and Chairman of the Board of Directors of Rainier Therapeutics, Inc., a private oncology-focused biotechnology company, from 2018 to 2020 when its lead asset was purchased by Fusion Pharmaceuticals Inc., and as President, Chief Executive Officer and a member of the Board of Directors of Cascadian Therapeutics Inc. (fkaOncothyreon, Inc.), or Cascadian, from 2016 until it was acquired by Seagen, Inc. (fka Seattle Genetics, Inc.), or Seagen, in 2018. Mr. Myers has served as Chairperson of the Board of Directors of Convergent Therapeutics, Inc. since March 2024, as Chairperson of the Board of Directors of Dynavax Technologies Corporation, or Dynavax (Nasdaq: DVAX), since October 2021, and as a member of the Board of Directors of Umoja Biopharma, Inc. since November 2024. Mr. Myers also served as a member of the Board of Directors of Harpoon Therapeutics, Inc., or Harpoon, from August 2018, and as Chairman of Harpoon from October 2021, until Harpoon was acquired by Merck & Co., Inc., or Merck (NYSE: MRK), in March 2024. Mr. Myers previously served as a member of the Boards of Directors of Selecta Biosciences, Inc. from June 2019 until its merger with Cartesian Therapeutics, Inc. (Nasdaq: RNAC) in November 2023, and Trillium Therapeutics Inc., or Trillium, from April 2021 until its acquisition by Pfizer Inc., or Pfizer (NYSE: PFE), in November 2021, and as Chairperson of the Board of Directors of Ironshore Therapeutics Inc. from April 2022 until its acquisition by Collegium Pharmaceutical Inc. (Nasdaq: COLL) in September 2024, and Sensorion S.A. (EPA: ALSEN) from December 2021 to March 2023. Mr. Myers received a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago.
- Julie Eastland
-
Julie Eastland在本招股说明书所包含的注册声明生效后成为我们的董事会成员。Eastland女士自2020年2月起担任Eastland Advisory Services的顾问。在咨询之前，Eastland女士自2018年8月起担任生物技术公司Rainier Therapeutics，Inc.的首席财务官和商务官。在加入Rainier Therapeutics之前，Eastland女士曾于2010年9月至2018年3月被Seattle Genetics收购期间担任生物技术公司CascadianTherapeutics，Inc.的首席商务官兼首席财务官。在加入Cascadian之前，Eastland女士于2006年1月至2010年9月担任VLST Corporation（一家生物技术公司）的财务和行政首席财务官兼Vice President。在加入VLST Corporation之前，Eastland女士从2000年10月到2005年10月担任Dendreon Corporation（一家生物技术公司）战略规划Vice President。加入Dendreon之前，Eastland从1996年3月到1998年4月担任Amgen（一家生物制药公司）总监。Eastland女士目前在TSX上市公司Pascal Biosciences Inc.的董事会任职，并在纳斯达克上市公司HarpoonTherapeutics，Inc.和Dynavax Technologies的董事会任职。Eastland女士拥有科罗拉多州立大学（Colorado State University）的金融学学士学位和苏格兰爱丁堡大学赫里奥瓦特大学（Heriot-Watt University of the Edinburgh University）的工商管理硕士学位。
Julie Eastland,has served as President and Chief Executive Officer, and as a member of Board, since November 2024. Previously she served as the President and Chief Executive Officer of Harpoon from November 2021, and a member of its Board of Directors from October 2018, in each case until Harpoon's acquisition by Merck (NYSE: MRK) in March 2024. From October 2020 to November 2021, Ms. Eastland served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, Inc., or ReCode, a privately held genetics medicine company. Prior to ReCode, from October 2018 to February 2020, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, Inc., or Rainier, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian, a publicly traded biopharmaceutical company, from August 2010 to March 2018, when it was acquired by Seagen. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon Pharmaceuticals LLC and Amgen Inc. (Nasdaq: AMGN). Ms. Eastland serves as a member of the Boards of Directors of Lantheus Holdings, Inc. (Nasdaq: LNTH) and Seismic Therapeutic, Inc., and will continue to serve as a member of the Board of Directors of Dynavax (Nasdaq: DVAX) until May 2025. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University. - Julie Eastland在本招股说明书所包含的注册声明生效后成为我们的董事会成员。Eastland女士自2020年2月起担任Eastland Advisory Services的顾问。在咨询之前，Eastland女士自2018年8月起担任生物技术公司Rainier Therapeutics，Inc.的首席财务官和商务官。在加入Rainier Therapeutics之前，Eastland女士曾于2010年9月至2018年3月被Seattle Genetics收购期间担任生物技术公司CascadianTherapeutics，Inc.的首席商务官兼首席财务官。在加入Cascadian之前，Eastland女士于2006年1月至2010年9月担任VLST Corporation（一家生物技术公司）的财务和行政首席财务官兼Vice President。在加入VLST Corporation之前，Eastland女士从2000年10月到2005年10月担任Dendreon Corporation（一家生物技术公司）战略规划Vice President。加入Dendreon之前，Eastland从1996年3月到1998年4月担任Amgen（一家生物制药公司）总监。Eastland女士目前在TSX上市公司Pascal Biosciences Inc.的董事会任职，并在纳斯达克上市公司HarpoonTherapeutics，Inc.和Dynavax Technologies的董事会任职。Eastland女士拥有科罗拉多州立大学（Colorado State University）的金融学学士学位和苏格兰爱丁堡大学赫里奥瓦特大学（Heriot-Watt University of the Edinburgh University）的工商管理硕士学位。
- Julie Eastland,has served as President and Chief Executive Officer, and as a member of Board, since November 2024. Previously she served as the President and Chief Executive Officer of Harpoon from November 2021, and a member of its Board of Directors from October 2018, in each case until Harpoon's acquisition by Merck (NYSE: MRK) in March 2024. From October 2020 to November 2021, Ms. Eastland served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, Inc., or ReCode, a privately held genetics medicine company. Prior to ReCode, from October 2018 to February 2020, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, Inc., or Rainier, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian, a publicly traded biopharmaceutical company, from August 2010 to March 2018, when it was acquired by Seagen. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon Pharmaceuticals LLC and Amgen Inc. (Nasdaq: AMGN). Ms. Eastland serves as a member of the Boards of Directors of Lantheus Holdings, Inc. (Nasdaq: LNTH) and Seismic Therapeutic, Inc., and will continue to serve as a member of the Board of Directors of Dynavax (Nasdaq: DVAX) until May 2025. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
- Jan Skvarka
-
Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School. - Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
- Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School.
- David M. Johnson
-
DavidM.Johnson自2020年1月以来一直担任我们的董事会成员。Johnson先生是Velosbio的首席执行官，Velosbio是一家临床阶段的风险投资生物制药公司，自2017年共同创立公司以来，他一直担任该职位。从2013年到2016年，他曾任职Acerta Pharma公司（专注于肿瘤学的制药公司），在那里他曾担任首席执行官，在那里他曾领导公司实现所需的增长，以将阿卡鲁替尼从早期到后期的全球临床开发。他在Acerta的任职最终导致与AstraZeneca价值高达70亿美元的战略交易的执行。在加入Acerta Pharma公司之前，他在一些生物制药和梦百合公司，包括Calistoga Pharmaceuticals公司、Gloucester Pharmaceuticals公司、Millennium Pharmaceuticals公司、Immunex公司和Hoffman-La Roche公司担任各种职务，在临床开发、医疗事务、管道开发和商业方面的责任越来越大。约翰逊先生在印第安纳大学获得经济学学士学位。
David M. Johnson,has served as a member of Board since January 2020. Mr. Johnson also served as the Chairperson of Board from May 2022 to November 2024, and as the Lead Independent Director of Board from April 2020 to May 2022. Mr. Johnson is Chief Executive Officer and a member of the Board of Directors of Solve Therapeutics, Inc., a venture backed start-up focused on developing next generation mAb based oncology therapeutics, a position he has held since July 2021. In addition, Mr. Johnson is a general partner at Velosity Capital, a position he has held since January 2022. Previously, Mr. Johnson served as Chief Executive Officer of VelosBio Inc., or VelosBio, an oncology-focused biopharmaceutical company that he founded in 2017, which was acquired by Merck (NYSE: MRK) in December 2020. From 2013 to 2016, Mr. Johnson served as Chief Executive Officer of Acerta Pharma, LLC, an oncology-focused pharmaceutical company, which is now a member of the AstraZeneca Group (Nasdaq: AZN). Mr. Johnson has served as a member of the Board of Directors of Aura (Nasdaq: AURA), a biopharmaceutical company, since January 2021, and as Chairman of the Board of Directors of Aura since March 2021, as a member of the Board of Directors of Palleon Pharmaceuticals Inc., a biopharmaceutical company, since August 2021, as a member of the Board of Directors of Incisive Genetics Inc., a biotechnology company, since June 2022, and as a member of the Board of Directors of Sudo Biosciences, Inc., a biopharmaceutical company, since January 2021. Mr. Johnson has also served as the Chairman of the Board of Directors of Lengo Therapeutics, Inc., or Lengo, a precision oncology company, from March 2021 until it was acquired by Blueprint Medicines Corporation, or Blueprint (Nasdaq: BPMC), in December 2021. Mr. Johnson received a bachelor's degree from Indiana University. - DavidM.Johnson自2020年1月以来一直担任我们的董事会成员。Johnson先生是Velosbio的首席执行官，Velosbio是一家临床阶段的风险投资生物制药公司，自2017年共同创立公司以来，他一直担任该职位。从2013年到2016年，他曾任职Acerta Pharma公司（专注于肿瘤学的制药公司），在那里他曾担任首席执行官，在那里他曾领导公司实现所需的增长，以将阿卡鲁替尼从早期到后期的全球临床开发。他在Acerta的任职最终导致与AstraZeneca价值高达70亿美元的战略交易的执行。在加入Acerta Pharma公司之前，他在一些生物制药和梦百合公司，包括Calistoga Pharmaceuticals公司、Gloucester Pharmaceuticals公司、Millennium Pharmaceuticals公司、Immunex公司和Hoffman-La Roche公司担任各种职务，在临床开发、医疗事务、管道开发和商业方面的责任越来越大。约翰逊先生在印第安纳大学获得经济学学士学位。
- David M. Johnson,has served as a member of Board since January 2020. Mr. Johnson also served as the Chairperson of Board from May 2022 to November 2024, and as the Lead Independent Director of Board from April 2020 to May 2022. Mr. Johnson is Chief Executive Officer and a member of the Board of Directors of Solve Therapeutics, Inc., a venture backed start-up focused on developing next generation mAb based oncology therapeutics, a position he has held since July 2021. In addition, Mr. Johnson is a general partner at Velosity Capital, a position he has held since January 2022. Previously, Mr. Johnson served as Chief Executive Officer of VelosBio Inc., or VelosBio, an oncology-focused biopharmaceutical company that he founded in 2017, which was acquired by Merck (NYSE: MRK) in December 2020. From 2013 to 2016, Mr. Johnson served as Chief Executive Officer of Acerta Pharma, LLC, an oncology-focused pharmaceutical company, which is now a member of the AstraZeneca Group (Nasdaq: AZN). Mr. Johnson has served as a member of the Board of Directors of Aura (Nasdaq: AURA), a biopharmaceutical company, since January 2021, and as Chairman of the Board of Directors of Aura since March 2021, as a member of the Board of Directors of Palleon Pharmaceuticals Inc., a biopharmaceutical company, since August 2021, as a member of the Board of Directors of Incisive Genetics Inc., a biotechnology company, since June 2022, and as a member of the Board of Directors of Sudo Biosciences, Inc., a biopharmaceutical company, since January 2021. Mr. Johnson has also served as the Chairman of the Board of Directors of Lengo Therapeutics, Inc., or Lengo, a precision oncology company, from March 2021 until it was acquired by Blueprint Medicines Corporation, or Blueprint (Nasdaq: BPMC), in December 2021. Mr. Johnson received a bachelor's degree from Indiana University.
- Enoch Kariuki
-
Enoch Kariuki自2021年1月起担任我们的董事会成员。Kariuki博士从2020年8月到2021年1月担任Velosbio的首席财务官，该公司是Merck的子公司。在此之前，Kariuki博士于2018年6月至2020年2月担任赛诺菲子公司Synthorx的企业发展高级副总裁。此前，Kariuki博士从2014年5月到2018年4月担任H.I.G.BioHealth Partners of H.I.G.Capital的副总裁。Kariuki博士从2013年到2014年在Leerink Partners担任多个投资银行职位，从2011年到2013年在UBS Investment Bank担任多个职位。在此之前，他是Bristol-Myers Squibb的研发战略和分析博士后。Kariuki博士自2021年2月起担任ZentalisPharmaceuticals，Inc.（一家上市制药公司）的董事会成员。作为一名训练有素的药剂师，Kariuki博士拥有达特茅斯学院的工商管理硕士学位和药学博士学位。来自德克萨斯南方大学。
Enoch Kariuki has served as a member of board of directors since January 2021. Dr. Kariuki served as Chief Financial Officer of VelosBio, a subsidiary of Merck, from August 2020 until January 2021. Prior to that, Dr. Kariuki served as Senior Vice President, Corporate Development at Synthorx, a subsidiary of Sanofi, from June 2018 to February 2020. Previously, Dr. Kariuki served as Vice President, H.I.G. BioHealth Partners of H.I.G. Capital from May 2014 until April 2018. Dr. Kariuki held various roles in investment banking with Leerink Partners from 2013 to 2014 and with UBS Investment Bank from 2011 until 2013. Prior to that, he was a Post-Doctoral Fellow, R&D Strategy and Analytics at Bristol-Myers Squibb. Dr. Kariuki has served on the board of directors of Zentalis Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since February 2021. A pharmacist by training, Dr. Kariuki holds an M.B.A. from Dartmouth College and a Pharm.D. from Texas Southern University. - Enoch Kariuki自2021年1月起担任我们的董事会成员。Kariuki博士从2020年8月到2021年1月担任Velosbio的首席财务官，该公司是Merck的子公司。在此之前，Kariuki博士于2018年6月至2020年2月担任赛诺菲子公司Synthorx的企业发展高级副总裁。此前，Kariuki博士从2014年5月到2018年4月担任H.I.G.BioHealth Partners of H.I.G.Capital的副总裁。Kariuki博士从2013年到2014年在Leerink Partners担任多个投资银行职位，从2011年到2013年在UBS Investment Bank担任多个职位。在此之前，他是Bristol-Myers Squibb的研发战略和分析博士后。Kariuki博士自2021年2月起担任ZentalisPharmaceuticals，Inc.（一家上市制药公司）的董事会成员。作为一名训练有素的药剂师，Kariuki博士拥有达特茅斯学院的工商管理硕士学位和药学博士学位。来自德克萨斯南方大学。
- Enoch Kariuki has served as a member of board of directors since January 2021. Dr. Kariuki served as Chief Financial Officer of VelosBio, a subsidiary of Merck, from August 2020 until January 2021. Prior to that, Dr. Kariuki served as Senior Vice President, Corporate Development at Synthorx, a subsidiary of Sanofi, from June 2018 to February 2020. Previously, Dr. Kariuki served as Vice President, H.I.G. BioHealth Partners of H.I.G. Capital from May 2014 until April 2018. Dr. Kariuki held various roles in investment banking with Leerink Partners from 2013 to 2014 and with UBS Investment Bank from 2011 until 2013. Prior to that, he was a Post-Doctoral Fellow, R&D Strategy and Analytics at Bristol-Myers Squibb. Dr. Kariuki has served on the board of directors of Zentalis Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since February 2021. A pharmacist by training, Dr. Kariuki holds an M.B.A. from Dartmouth College and a Pharm.D. from Texas Southern University.
- Luke Walker
-
卢克·沃克，自2024年5月起担任董事会成员。Walker博士自2025年1月起担任Umoja Biopharma，Inc.的首席医疗官，该公司是一家专注于开发体内CAR T细胞疗法的公司。他此前在Harpoon担任首席医疗官，Harpoon是一家专注于肿瘤学的生物制药公司，专注于肿瘤学领域T细胞接合剂的开发，2022年10月至2024年3月，当时Harpoon被默沙东（纽约证券交易所代码：MRK）收购。从2018年3月到2022年9月，Walker博士担任Seagen临床开发副总裁，在那里他最初领导了TUKYSA（图卡替尼）以及后来的早期阶段项目组合的开发。在此之前，从2011年到2018年，Walker博士在Cascadian的临床开发部门担任过各种职务，Cascadian是一家上市的生物制药公司，已被Seagen收购，最终担任临床开发高级副总裁。Walker博士于2007年至2011年在华盛顿州埃弗雷特的普罗维登斯地区医疗中心担任内科肿瘤学家和血液学家，并于2005年至2007年在癌症护理中心埃弗雷特诊所担任。Walker博士自2024年9月起担任Context Therapeutics Inc.（纳斯达克：CNTX）的董事会成员，该公司是一家专注于肿瘤学的生物制药公司。Walker博士目前是美国内科委员会医学肿瘤学外交官，之前拥有血液学和内科委员会认证。他在俄勒冈Health Sciences大学完成了骨髓和干细胞移植以及血液学和医学肿瘤学方面的研究金。Walker博士在俄克拉荷马大学Health Sciences中心获得医学博士学位，在俄克拉荷马大学获得文学和法语学士学位。沃克博士还在2017年完成了斯坦福商学院LGBTQ高管领导力项目。
Luke Walker,has served as a member of Board since May 2024. Dr. Walker has served as the Chief Medical Officer of Umoja Biopharma, Inc., a company focused on the development of in vivo CAR T cell therapeutics, since January 2025. He previously was the Chief Medical Officer of Harpoon, an oncology-focused biopharmaceutical company focused on the development of T-cell engagers in oncology, from October 2022 to March 2024, when Harpoon was acquired by Merck (NYSE: MRK). From March 2018 to September 2022, Dr. Walker served as Vice President, Clinical Development for Seagen, where he initially led the development of TUKYSA (tucatinib) and later, a portfolio of early stage programs. Prior to that, from 2011 to 2018, Dr. Walker held various roles in clinical development at Cascadian, a publicly traded biopharmaceutical company that was acquired by Seagen, culminating in his role as Senior Vice President, Clinical Development. Dr. Walker served as a medical oncologist and hematologist at Providence Regional Medical Center, Everett, WA, from 2007 to 2011 and at The Everett Clinic, Center for Cancer Care, from 2005 to 2007. Dr. Walker has served as a member of the Board of Directors of Context Therapeutics Inc. (Nasdaq: CNTX), an oncology-focused biopharmaceutical company, since September 2024. Dr. Walker is a current Diplomate of the American Board of Internal Medicine in Medical Oncology, with prior board certifications in Hematology and Internal Medicine. He completed fellowships in bone marrow and stem cell transplantation, and hematology and medical oncology at Oregon Health Sciences University. Dr. Walker received his M.D. from the University of Oklahoma Health Sciences Center and his B.A. in letters and French from the University of Oklahoma. Dr. Walker also completed the Stanford Graduate School of Business LGBTQ Executive Leadership Program in 2017. - 卢克·沃克，自2024年5月起担任董事会成员。Walker博士自2025年1月起担任Umoja Biopharma，Inc.的首席医疗官，该公司是一家专注于开发体内CAR T细胞疗法的公司。他此前在Harpoon担任首席医疗官，Harpoon是一家专注于肿瘤学的生物制药公司，专注于肿瘤学领域T细胞接合剂的开发，2022年10月至2024年3月，当时Harpoon被默沙东（纽约证券交易所代码：MRK）收购。从2018年3月到2022年9月，Walker博士担任Seagen临床开发副总裁，在那里他最初领导了TUKYSA（图卡替尼）以及后来的早期阶段项目组合的开发。在此之前，从2011年到2018年，Walker博士在Cascadian的临床开发部门担任过各种职务，Cascadian是一家上市的生物制药公司，已被Seagen收购，最终担任临床开发高级副总裁。Walker博士于2007年至2011年在华盛顿州埃弗雷特的普罗维登斯地区医疗中心担任内科肿瘤学家和血液学家，并于2005年至2007年在癌症护理中心埃弗雷特诊所担任。Walker博士自2024年9月起担任Context Therapeutics Inc.（纳斯达克：CNTX）的董事会成员，该公司是一家专注于肿瘤学的生物制药公司。Walker博士目前是美国内科委员会医学肿瘤学外交官，之前拥有血液学和内科委员会认证。他在俄勒冈Health Sciences大学完成了骨髓和干细胞移植以及血液学和医学肿瘤学方面的研究金。Walker博士在俄克拉荷马大学Health Sciences中心获得医学博士学位，在俄克拉荷马大学获得文学和法语学士学位。沃克博士还在2017年完成了斯坦福商学院LGBTQ高管领导力项目。
- Luke Walker,has served as a member of Board since May 2024. Dr. Walker has served as the Chief Medical Officer of Umoja Biopharma, Inc., a company focused on the development of in vivo CAR T cell therapeutics, since January 2025. He previously was the Chief Medical Officer of Harpoon, an oncology-focused biopharmaceutical company focused on the development of T-cell engagers in oncology, from October 2022 to March 2024, when Harpoon was acquired by Merck (NYSE: MRK). From March 2018 to September 2022, Dr. Walker served as Vice President, Clinical Development for Seagen, where he initially led the development of TUKYSA (tucatinib) and later, a portfolio of early stage programs. Prior to that, from 2011 to 2018, Dr. Walker held various roles in clinical development at Cascadian, a publicly traded biopharmaceutical company that was acquired by Seagen, culminating in his role as Senior Vice President, Clinical Development. Dr. Walker served as a medical oncologist and hematologist at Providence Regional Medical Center, Everett, WA, from 2007 to 2011 and at The Everett Clinic, Center for Cancer Care, from 2005 to 2007. Dr. Walker has served as a member of the Board of Directors of Context Therapeutics Inc. (Nasdaq: CNTX), an oncology-focused biopharmaceutical company, since September 2024. Dr. Walker is a current Diplomate of the American Board of Internal Medicine in Medical Oncology, with prior board certifications in Hematology and Internal Medicine. He completed fellowships in bone marrow and stem cell transplantation, and hematology and medical oncology at Oregon Health Sciences University. Dr. Walker received his M.D. from the University of Oklahoma Health Sciences Center and his B.A. in letters and French from the University of Oklahoma. Dr. Walker also completed the Stanford Graduate School of Business LGBTQ Executive Leadership Program in 2017.
- Shannon Campbell
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- James B. Bucher
James B. Bucher，他担任高级副总裁兼法律总顾问（2016年1月以来）。2015年期间，他曾担任顾问，并为几个生命科学公司提供法律服务。2007年至2014年，他曾担任Exelixis, Inc.（生物制药公司）的公司法律事务副总裁和秘书、企业合规官。1991年至2007年，他曾担任Shearman & Sterling LLP的国际律师事务所的公司律师，并于2001年成为合伙人。他获得Emory大学School of Law的荣誉法学博士学位，以及Colgate大学的生物学学士学位。
James B. Bucher has served as Executive Vice President and General Counsel since October 2020. Prior to joining Eliem, Mr. Bucher served as Executive Vice President and General Counsel of Alder from 2016 until its acquisition by H. Lundbeck in 2019. During 2015 Mr. Bucher served as a consultant providing legal services to several life sciences companies. From 2007 to 2014 Mr. Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a biopharmaceutical company. Previously, Mr. Bucher was a partner at the international law firm of Shearman and Sterling LLP, serving with the firm for 16 years. Mr. Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University.- James B. Bucher，他担任高级副总裁兼法律总顾问（2016年1月以来）。2015年期间，他曾担任顾问，并为几个生命科学公司提供法律服务。2007年至2014年，他曾担任Exelixis, Inc.（生物制药公司）的公司法律事务副总裁和秘书、企业合规官。1991年至2007年，他曾担任Shearman & Sterling LLP的国际律师事务所的公司律师，并于2001年成为合伙人。他获得Emory大学School of Law的荣誉法学博士学位，以及Colgate大学的生物学学士学位。
- James B. Bucher has served as Executive Vice President and General Counsel since October 2020. Prior to joining Eliem, Mr. Bucher served as Executive Vice President and General Counsel of Alder from 2016 until its acquisition by H. Lundbeck in 2019. During 2015 Mr. Bucher served as a consultant providing legal services to several life sciences companies. From 2007 to 2014 Mr. Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a biopharmaceutical company. Previously, Mr. Bucher was a partner at the international law firm of Shearman and Sterling LLP, serving with the firm for 16 years. Mr. Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University.
- Julie Eastland
Julie Eastland在本招股说明书所包含的注册声明生效后成为我们的董事会成员。Eastland女士自2020年2月起担任Eastland Advisory Services的顾问。在咨询之前，Eastland女士自2018年8月起担任生物技术公司Rainier Therapeutics，Inc.的首席财务官和商务官。在加入Rainier Therapeutics之前，Eastland女士曾于2010年9月至2018年3月被Seattle Genetics收购期间担任生物技术公司CascadianTherapeutics，Inc.的首席商务官兼首席财务官。在加入Cascadian之前，Eastland女士于2006年1月至2010年9月担任VLST Corporation（一家生物技术公司）的财务和行政首席财务官兼Vice President。在加入VLST Corporation之前，Eastland女士从2000年10月到2005年10月担任Dendreon Corporation（一家生物技术公司）战略规划Vice President。加入Dendreon之前，Eastland从1996年3月到1998年4月担任Amgen（一家生物制药公司）总监。Eastland女士目前在TSX上市公司Pascal Biosciences Inc.的董事会任职，并在纳斯达克上市公司HarpoonTherapeutics，Inc.和Dynavax Technologies的董事会任职。Eastland女士拥有科罗拉多州立大学（Colorado State University）的金融学学士学位和苏格兰爱丁堡大学赫里奥瓦特大学（Heriot-Watt University of the Edinburgh University）的工商管理硕士学位。
Julie Eastland,has served as President and Chief Executive Officer, and as a member of Board, since November 2024. Previously she served as the President and Chief Executive Officer of Harpoon from November 2021, and a member of its Board of Directors from October 2018, in each case until Harpoon's acquisition by Merck (NYSE: MRK) in March 2024. From October 2020 to November 2021, Ms. Eastland served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, Inc., or ReCode, a privately held genetics medicine company. Prior to ReCode, from October 2018 to February 2020, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, Inc., or Rainier, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian, a publicly traded biopharmaceutical company, from August 2010 to March 2018, when it was acquired by Seagen. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon Pharmaceuticals LLC and Amgen Inc. (Nasdaq: AMGN). Ms. Eastland serves as a member of the Boards of Directors of Lantheus Holdings, Inc. (Nasdaq: LNTH) and Seismic Therapeutic, Inc., and will continue to serve as a member of the Board of Directors of Dynavax (Nasdaq: DVAX) until May 2025. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.- Julie Eastland在本招股说明书所包含的注册声明生效后成为我们的董事会成员。Eastland女士自2020年2月起担任Eastland Advisory Services的顾问。在咨询之前，Eastland女士自2018年8月起担任生物技术公司Rainier Therapeutics，Inc.的首席财务官和商务官。在加入Rainier Therapeutics之前，Eastland女士曾于2010年9月至2018年3月被Seattle Genetics收购期间担任生物技术公司CascadianTherapeutics，Inc.的首席商务官兼首席财务官。在加入Cascadian之前，Eastland女士于2006年1月至2010年9月担任VLST Corporation（一家生物技术公司）的财务和行政首席财务官兼Vice President。在加入VLST Corporation之前，Eastland女士从2000年10月到2005年10月担任Dendreon Corporation（一家生物技术公司）战略规划Vice President。加入Dendreon之前，Eastland从1996年3月到1998年4月担任Amgen（一家生物制药公司）总监。Eastland女士目前在TSX上市公司Pascal Biosciences Inc.的董事会任职，并在纳斯达克上市公司HarpoonTherapeutics，Inc.和Dynavax Technologies的董事会任职。Eastland女士拥有科罗拉多州立大学（Colorado State University）的金融学学士学位和苏格兰爱丁堡大学赫里奥瓦特大学（Heriot-Watt University of the Edinburgh University）的工商管理硕士学位。
- Julie Eastland,has served as President and Chief Executive Officer, and as a member of Board, since November 2024. Previously she served as the President and Chief Executive Officer of Harpoon from November 2021, and a member of its Board of Directors from October 2018, in each case until Harpoon's acquisition by Merck (NYSE: MRK) in March 2024. From October 2020 to November 2021, Ms. Eastland served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, Inc., or ReCode, a privately held genetics medicine company. Prior to ReCode, from October 2018 to February 2020, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, Inc., or Rainier, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian, a publicly traded biopharmaceutical company, from August 2010 to March 2018, when it was acquired by Seagen. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon Pharmaceuticals LLC and Amgen Inc. (Nasdaq: AMGN). Ms. Eastland serves as a member of the Boards of Directors of Lantheus Holdings, Inc. (Nasdaq: LNTH) and Seismic Therapeutic, Inc., and will continue to serve as a member of the Board of Directors of Dynavax (Nasdaq: DVAX) until May 2025. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
- Ingmar Bruns
Ingmar Bruns自2020年11月2日起担任Trillium的首席医疗官。此前，Bruns博士于2017年10月至2020年11月担任Pieris Pharmaceuticals的高级副总裁兼临床开发主管，并于2013年7月至2017年10月担任Bayer Pharmaceuticals的多个肿瘤资产的临床开发主管，担任首席医疗官，Bruns博士负责我们临床和监管策略的设计和执行。
Ingmar Bruns has been the Chief Medical Officer of Trillium since November 2 2020. Previously, Dr. Bruns was the senior vice president and head of clinical development at Pieris Pharmaceuticals from October 2017 to November 2020 and from July 2013 through October 2017 Dr. Bruns led clinical development of several oncology assets at Bayer Pharmaceuticals.As Chief Medical Officer, Dr. Bruns is responsible for the design and execution of clinical and regulatory strategy.- Ingmar Bruns自2020年11月2日起担任Trillium的首席医疗官。此前，Bruns博士于2017年10月至2020年11月担任Pieris Pharmaceuticals的高级副总裁兼临床开发主管，并于2013年7月至2017年10月担任Bayer Pharmaceuticals的多个肿瘤资产的临床开发主管，担任首席医疗官，Bruns博士负责我们临床和监管策略的设计和执行。
- Ingmar Bruns has been the Chief Medical Officer of Trillium since November 2 2020. Previously, Dr. Bruns was the senior vice president and head of clinical development at Pieris Pharmaceuticals from October 2017 to November 2020 and from July 2013 through October 2017 Dr. Bruns led clinical development of several oncology assets at Bayer Pharmaceuticals.As Chief Medical Officer, Dr. Bruns is responsible for the design and execution of clinical and regulatory strategy.